The hallmark of ECT’s efficacy lies in its ability to induce controlled seizures under general anesthesia, which paradoxically leads to marked improvements in psychiatric symptoms, especially in major depressive disorder (MDD) and certain psychotic illnesses. Early clinical observations documented its rapid mood-enhancing effects, but the variability in patient outcomes necessitated a deeper search for biomarkers. These markers are critical not only for improving patient selection and reducing cognitive side effects but also for unraveling the complex pathophysiology of treatment-resistant depression.

A key clinical challenge addressed by the review is the heterogeneity of patient responses. While some patients exhibit dramatic remission, others derive minimal benefit. This variability suggests underlying neurobiological differences. Hence, the authors emphasize the role of clinical parameters such as symptom clusters, illness duration, and comorbidities as initial predictors. More granular clinical features, including baseline cognitive function and psychomotor retardation, are correlated with differential outcomes, hinting at distinct neural circuit involvement and neuroplasticity potential.

Venturing beyond clinical descriptors, the review meticulously catalogues neuroimaging findings as promising biological markers. Structural and functional MRI studies highlight the normalization of aberrant connectivity patterns in the prefrontal cortex, hippocampus, and limbic system post-ECT. Changes in cortical thickness and hippocampal volume appear as reliable correlates of clinical improvement, implicating ECT-triggered neurogenesis and synaptic remodeling. Importantly, resting-state functional connectivity analyses reveal shifts in the default mode network and salience network activity, which may underpin symptom alleviation mechanisms.

Electroencephalography (EEG) has also emerged as an invaluable tool in the biomarker landscape. Alterations in spectral power, particularly increased theta and delta rhythms during seizures, are associated with positive treatment response. Pre-ECT EEG patterns also serve predictive functions; patients exhibiting specific baseline slow-wave activity tend to respond more favorably. This electrophysiological data not only enhances treatment customization but also provides real-time markers to optimize ECT parameters such as stimulus intensity and seizure duration.

At the molecular and cellular biology level, the review synthesizes evidence implicating neurotrophic factors as central mediators of ECT effectiveness. Brain-derived neurotrophic factor (BDNF), known for its role in neuronal survival and synaptic plasticity, increases significantly following therapy. Parallel changes in inflammatory markers suggest an interplay between immune modulation and neuroplastic processes. The authors highlight that ECT’s capacity to modulate neuroinflammation and promote neurogenesis could represent the biological substrate for sustained symptom remission.

Genetic and epigenetic investigations further deepen insight into ECT response variability. Polymorphisms in genes regulating neurotransmitter systems, neurotrophic signaling, and stress response pathways may predict both efficacy and side effect susceptibility. Epigenetic modifications, such as DNA methylation changes in key regulatory genes, are emerging as dynamic biomarkers that could reflect the biological imprint of treatment. These molecular markers pave the way for personalized medicine approaches where genetic profiling informs individualized ECT protocols.

One of the most intriguing advances discussed is the potential for integrating multimodal biomarker data into predictive algorithms. Machine learning techniques applied to clinical scores, neuroimaging metrics, EEG parameters, and molecular profiles demonstrate enhanced accuracy in forecasting ECT outcomes. This multidimensional biomarker strategy marks a pivotal step toward clinical decision support systems, allowing psychiatrists to strike a balance between maximal therapeutic effect and minimal cognitive risk.

Cognitive side effects remain a clinical concern, particularly with bilateral electrode placement. The review outlines how emerging biomarkers could predict cognitive trajectories post-ECT, enabling optimized electrode positioning and dosage tailoring. Functional imaging studies indicate that selective modulation of hippocampal circuits is crucial to preserving memory function, a finding that could guide future technical refinements in ECT administration.

Importantly, the authors advocate for longitudinal biomarker assessments throughout the treatment course, emphasizing the dynamic nature of biological response. Real-time biomarker monitoring could inform adaptive therapy protocols, identifying early responders and non-responders to modify treatment plans in real time. This approach aligns with the evolving paradigm of precision psychiatry that transcends static diagnosis-based frameworks.

The review also discusses the ethical and methodological challenges in biomarker research, including cohort heterogeneity, small sample sizes, and technical variability across centers. Standardization of protocols and international consortia for data sharing are proposed as solutions to accelerate biomarker validation and ultimately clinical translation. Moreover, integrating patient-reported outcomes and functional measures complements biological markers for a holistic picture of treatment impact.

Looking ahead, the synthesis provided in this narrative review sets the stage for innovative clinical trials that incorporate biomarker-guided stratification. The emerging biomarker profiles could identify novel therapeutic targets and facilitate combination strategies, such as augmenting ECT with pharmacotherapy or brain stimulation techniques tailored to individual biological profiles. Such synergistic approaches promise to enhance clinical efficacy while mitigating adverse effects.

In conclusion, the comprehensive evaluation of clinical and biological markers reviewed by Zilles-Wegner and colleagues represents a major milestone in understanding ECT’s intricate mechanisms. By bridging clinical phenomenology with cutting-edge neuroscience, this work propels the field toward predictive and personalized psychiatry. As technological and computational advancements converge with deeper biological insights, the vision of tailored, efficient, and safe ECT treatments moves within reach, offering hope for millions afflicted by treatment-resistant psychiatric disorders.

Subject of Research: Clinical and biological markers predicting the effectiveness of electroconvulsive therapy in treatment-resistant psychiatric disorders

Article Title: Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review

Article References:
Zilles-Wegner, D., von Mücke-Heim, IA., Yrondi, A. et al. Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03900-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03900-2

ECT, traditionally viewed as a potentially life-saving intervention for severe depression and other psychiatric disorders, has been controversial due to concerns regarding its cognitive side effects and ethical implications. While some recipients report mood improvements and reduced suicidality, the study strikingly documents that more than half of participants (51%) experienced solely negative effects, highlighting a troubling disparity between clinical narratives and patient realities. This large-scale participant-reported data offers a rare glimpse into the long-term adverse impacts, often overlooked or minimized in clinical trials and regulatory assessments.

One of the most alarming revelations is the prevalence of persistent memory loss, which 82% of respondents identified as a consequence of ECT. This figure significantly exceeds prior clinical estimates, which typically underreport the extent and severity of memory impairments. Participants described disruptions in both retrograde and anterograde memory, underscoring a profound cognitive decline that hampers daily function, identity coherence, and quality of life. Such memory disturbances suggest that ECT may impart lasting neurobiological damage, calling into question the longstanding assumption that cognitive side effects are transient.

Beyond the cognitive domain, many recipients articulated experiences that transcended traditional symptom checklists. Approximately 29% reported “cognitive decline” in broader terms, implicating deficits in executive functioning, attention, and information processing speed. Moreover, 8% expressed feelings of having been “violated” by the procedure, evocative of psychological trauma. This qualitative dimension—accessed through open-ended survey questions—captures the emotional and existential toll of ECT, a facet rarely addressed in quantitative outcome studies but critical to comprehensive patient care.

The psychosocial ramifications surfaced as another critical concern. A striking 33% of participants reported job loss attributable to the aftermath of ECT, while a substantial 68% indicated relationship difficulties post-treatment. These statistics implicate not just neurological impairment but also social isolation, reduced employability, and diminished interpersonal trust. Such consequences underscore the necessity for an integrated approach to patient assessment, one that extends beyond symptom alleviation to encompass functional, social, and occupational domains.

The study’s methodological innovation lies in prioritizing patient voices through open questions rather than relying on predefined symptom lists. By doing so, the research uncovers nuanced adverse effects, including some that have historically been marginalized or omitted from medical discourse. This approach reveals a landscape where the clinical benefits claimed — such as a positive impact on depression (reported by 23%) and reduction in suicidality (13%) — must be weighed against a broad spectrum of potentially debilitating side effects.

Critically, the research team includes members with lived experience of ECT, alongside clinical psychologists, ensuring a multidimensional perspective that bridges scientific rigor with patient advocacy. Their findings challenge the psychiatric community to reconcile clinical guidelines with patient realities, advocating for transparent risk communication and the development of robust monitoring protocols. The team explicitly calls for further research that rigorously evaluates the benefit-risk ratio of ECT, emphasizing the importance of incorporating long-term adverse effect data into safety assessments and regulatory frameworks.

Lead researcher Professor John Read, a distinguished clinical psychologist, underscores the discrepancy between reported patient experiences and psychiatrists’ prevailing reassurances about ECT’s safety. Highlighting memory loss as one of the most consistently documented adverse effects, he points out that existing estimates vastly underestimate patient-reported severity and persistence. Read also stresses the psychological trauma inflicted by the treatment process and its cascading effects on social and occupational functioning—topics often neglected in mainstream psychiatric literature.

Adding a personal dimension, co-author and ECT survivor Lisa Morrison voices frustration at enduring neglect and systemic silencing of patients harmed by ECT. Morrison raises ethical and human rights concerns, emphasizing the absence of mechanisms for ongoing monitoring, rehabilitation, and support for those affected by the therapy’s debilitating consequences. Her commentary highlights the power imbalances inherent in psychiatric practice and regulatory oversight, echoing calls for reform grounded in respect and empathy for patient experiences.

Another co-author, Sue Cunliffe, a former medical doctor incapacitated by ECT-induced cognitive impairment, provides a clinical yet personal testament to the reality of brain injury following the procedure. Diagnosed by a neuropsychologist with specific brain damage attributable to ECT, her narrative confronts the frequently asserted notion that ECT cannot cause permanent neurological harm. This case exemplifies the urgent need for unbiased neuropsychological evaluations in post-ECT care and a reevaluation of clinical assumptions.

The study has garnered attention from mental health advocacy organizations, including Mind, whose Information Content Manager, Rosie Weatherley, echoes the researchers’ concerns. Mind calls for a comprehensive re-examination of ECT’s role in psychiatric treatment, emphasizing the necessity for evidence-based therapies that do not pose comparable risks. They advocate for increased funding and research to identify safer and more effective alternatives that prioritize patient wellbeing and informed consent.

Published in the Journal of Affective Disorders Reports, this landmark survey punctuates ongoing debates about ECT’s place in mental health treatment paradigms. It compels clinicians, policymakers, and researchers to rigorously scrutinize the true extent of adverse effects and to integrate patient-reported outcomes into the evaluation of psychiatric interventions. By centering patient narratives and employing innovative methodologies, this study illuminates the hidden complexities of ECT’s impact, urging a shift towards more compassionate, transparent, and ethically sound psychiatric care.

Ultimately, this research challenges the prevailing optimism surrounding ECT, revealing a more nuanced and troubling picture. It calls for an urgent reassessment of clinical practices, regulatory standards, and patient communication to ensure that decisions surrounding ECT are grounded in a balanced understanding of its benefits and harms. The findings implore the psychiatric community to move beyond reductionist efficacy models, embracing a holistic framework that honors patient experiences and prioritizes long-term health and dignity.

Subject of Research: The long-term self-reported positive and negative effects of Electroconvulsive Therapy (ECT) based on an international patient survey.

Article Title: ‘The self-reported positive and negative effects of electroconvulsive therapy: an international survey’

News Publication Date: February 3, 2026

Web References:

• Journal of Affective Disorders Reports: https://www.sciencedirect.com/science/article/pii/S2666915325001386
• DOI: 10.1016/j.jadr.2025.101008

References:

• Read, J., Cunliffe, S., Hancock, S.P., Harrop, C., Johnstone, L., Morrison, L. (2025). ‘The self-reported positive and negative effects of electroconvulsive therapy: an international survey’, Journal of Affective Disorders Reports.
• Additional related publications on ECT authored by the same research group in journals such as International Journal of Mental Health Nursing, Health Care for Women International, Journal of Medical Ethics, and Ethical Human Psychology and Psychiatry.

Keywords: Psychological science, Clinical psychology, Mental health, Electroconvulsive Therapy, Cognitive impairment, Memory loss, Patient-reported outcomes, Psychiatric treatment risks, Neuropsychological injury, Mental health ethics

Traditionally, the psychiatric community has adhered to relatively rigid treatment regimens, typically advocating between six to twelve ECT sessions. However, the new review spearheaded by Professor Yanghua Tian from Anhui Medical University challenges this convention by revealing a more complex dose-response curve. Their findings indicate that the bulk of symptomatic relief occurs early in the treatment course, with approximately a 26% reduction in depression severity following just one session, and nearly 50% improvement by the third. This rapid early response suggests that the conventional extended course model may not be universally necessary or optimal.

A central revelation from this review is the identification of distinct patient response trajectories. Approximately one-quarter of patients exhibit swift remission within a handful of sessions, while a significant subset shows moderate, incremental improvements. Alarmingly, a notable minority—roughly 13%—display minimal response even after prolonged ECT courses. This heterogeneity suggests the potential of tailored treatment strategies, rather than the prevailing one-size-fits-all protocols. It raises the pressing clinical question of how to preemptively discern responders from non-responders or slow responders.

Such distinctions are not academic but critical, because prolonged ECT administration carries a quantifiable cognitive toll. Memory impairment and other cognitive deficits emerge surprisingly early, sometimes as soon as the second ECT session, accumulating with subsequent treatments. This cumulative burden presents a clinical paradox: while additional sessions may provide limited incremental benefit for some, they simultaneously compound patients’ cognitive risks. This finding underscores the need for precision dosing and stringent monitoring throughout the treatment course.

The paradigm shift proposed by the authors advocates for a "response-guided sequential treatment" approach. Instead of adhering to a fixed number of sessions prescribed a priori, this strategy calls for dynamic adjustments based on real-time patient response. Notably, ECT is envisioned as the initial ‘leg’ of a relay, delivering rapid mood stabilization within 3 to 6 sessions for responders, after which care transitions toward safer maintenance therapies such as non-invasive brain stimulation techniques or psychotherapy. For slow or non-responders, alternatives like ketamine augmentation or entirely different modalities might be indicated earlier in the treatment course.

Underlying this shift are compelling neurobiological insights that unveil how the brain adapts during ECT. Advanced neuroimaging reveals that hippocampal volume—central to memory processing—progressively increases through the treatment course. This volumetric plasticity aligns with changes in neurotransmitter systems and inflammatory markers, highlighting a complex adaptive cascade triggered by induced seizures. These dynamic processes imply that the brain does more than merely endure ECT; it actively remodels itself, with implications for both therapeutic efficacy and adverse side effects.

Interestingly, seizure duration has traditionally been employed as a marker of treatment adequacy within ECT protocols, with longer seizures often equated to better outcomes. However, the review documents a marked decrease in seizure duration over successive sessions. This counterintuitive trend provokes pivotal questions: does declining seizure length indicate emerging treatment resistance, or is it reflective of adaptive neural mechanisms mitigating seizure propagation? Addressing this could lead to refinements in how treatment adequacy is assessed in clinical practice.

The integration of biomarkers, including serum brain-derived neurotrophic factor (BDNF) and cortisol levels, adds a further dimension to understanding ECT’s neurophysiological footprint. These biomarkers exhibit transient spikes immediately post-session, normalizing over time, painting a picture of highly dynamic systemic responses. Such patterns evoke the tantalizing possibility that future treatment could be guided not solely by clinical scales but augmented by objective biological signals, enhancing personalized treatment strategies.

The implications for psychiatry are potentially transformative. By coupling rigorous symptom monitoring with cognitive assessments and biomarker data, clinicians might soon implement more agile, patient-specific regimens that maximize remission while sparing cognitive function. This approach could challenge entrenched treatment paradigms and reduce the stigma often associated with ECT’s cognitive side effects, thereby improving patient acceptance and access to this life-saving intervention.

Beyond individual patient benefits, the potential system-level advantages are notable. Given that many healthcare systems face limited ECT capacity and increasing depression prevalence, adopting a response-guided methodology could optimize resource utilization. Shorter average treatment parcels without compromising efficacy would enable more patients to benefit from ECT. Equally, patients hesitant to undergo ECT owing to fears of cognitive decline may find reassurance in protocols designed to minimize exposure.

However, numerous questions remain unanswered, inviting further rigorous research. The long-term relapse rates following early termination of ECT and transition to adjunctive therapies warrant careful investigation. Whether combination approaches initiated after fewer ECT sessions may outperform extended monotherapy remains an open query. Additionally, the integration of emerging neurostimulation technologies like transcranial magnetic stimulation within these sequential frameworks poses exciting possibilities for future clinical innovation.

The review’s authors advocate for the development of predictive algorithms integrating clinical features, imaging, biomarkers, and early response patterns to refine individualized treatment plans. Such precision medicine approaches are well poised to revolutionize psychiatric practice, ushering in an era where ECT is wielded with surgical precision, maximizing benefit while mitigating harm.

In summation, this landmark review elucidates a new era in ECT treatment, moving away from rigid, protocol-driven courses to adaptive, response-informed strategies. It heralds a future in which ECT’s profound efficacy in combating severe depression is harnessed with unprecedented accuracy and safety. As mental health challenges continue to mount globally, such innovations promise to reshape therapeutic paradigms, offering hope for improved outcomes and enhanced quality of life for millions living with treatment-resistant depression.

Subject of Research: People

Article Title: Rethinking the impact and management of electroconvulsive therapy session number in depression

News Publication Date: 3 June 2025

References:
Tian, Y., Ji, Y., et al. (2025). Rethinking the impact and management of electroconvulsive therapy session number in depression. Brain Medicine. DOI: 10.61373/bm025i.0053

Image Credits: Yanghua Tian

Keywords: Electroconvulsive therapy, ECT dosing, depression treatment, cognitive side effects, response-guided therapy, neurobiology, biomarkers, hippocampal plasticity, precision psychiatry, treatment-resistant depression